Cosciens Biopharma
(TSX) AEZS
Cosciens Biopharma Financials at a Glance
Market Cap
N/A
Revenue (TTM)
$2.46M
Net Income (TTM)
$5.24M
EPS (TTM)
N/A
P/E Ratio
N/A
Dividend
N/A
Beta (Volatility)
N/A
Dividend
N/A
Beta (Volatility)
N/A
Price
N/A
Volume
N/A
Open
N/A
Price
N/A
Volume
N/A
Open
N/A
Previous Close
N/A
Daily Range
N/A
52-Week Range
N/A
Dividend
N/A
Beta (Volatility)
N/A
Price
N/A
Volume
N/A
Open
N/A
Previous Close
N/A
Daily Range
N/A
52-Week Range
N/A
AEZS News
Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Cosciens Biopharma
Industry
Biotechnology
Sector
Health CareEmployees
28
CEO
Peter Harry Puccetti, CFA
Website
www.cosciensbio.comHeadquarters
Summerville, SC 29486, US
AEZS Financials
Key Financial Metrics (TTM)
Gross Margin
32%
Operating Margin
-1%
Net Income Margin
-1%
Return on Equity
-2%
Return on Capital
-60%
Return on Assets
-49%
Earnings Yield
N/A
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
N/A
Shares Outstanding
N/A
Volume
N/A
Short Interest
N/A
Avg. Volume
N/A
Financials (TTM)
Gross Profit
$4.28M
Operating Income
$18.01M
EBITDA
$17.99M
Operating Cash Flow
$17.12M
Capital Expenditure
$19.00K
Free Cash Flow
$17.14M
Cash & ST Invst.
$34.02M
Total Debt
$3.39M
Cosciens Biopharma Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$2.34M
+4.1%
Gross Profit
$819.00K
-61.1%
Gross Margin
35.04%
N/A
Market Cap
N/A
N/A
Market Cap/Employee
N/A
N/A
Employees
12
N/A
Net Income
$1.42M
+43.5%
EBITDA
$3.27M
-361.1%
Quarterly Fundamentals
Net Cash
$26.12M
-37.8%
Accounts Receivable
$1.35M
+9.5%
Inventory
$3.06M
+3184.9%
Long Term Debt
$1.28M
-58.7%
Short Term Debt
$407.00K
+39.6%
Return on Assets
-48.56%
N/A
Return on Invested Capital
-60.24%
N/A
Free Cash Flow
$1.55M
+64.0%
Operating Cash Flow
$1.39M
+67.6%